Note 7 - PF Medical
|3 Months Ended|
Mar. 31, 2017
|Notes to Financial Statements|
|Perma-Fix Medical S.A. [Text Block]||
The Company’s Medical Segment (consists of our majority-owned Polish subsidiary, Perma-Fix Medical S.A. and its wholly-owned subsidiary, Perma-Fix Medical Corporation (“PFM Corporation”) (together known as “PF Medical”)) has not generated any revenue as it has been primarily in the research and development (“R&D”) stage.
During the latter part of
2016,the Medical Segment ceased a substantial portion of its R&D activities due to the need for substantial capital to fund such activities. The Medical Segment will not resume any substantial R&D activities until it obtains the necessary funding through obtaining its own credit facility or additional equity raise.
2016,the Company and its Medical Segment entered into a letter of intent (“LOI”) with a private investor, subject to certain closing and other conditions, including, but not limited to, the execution of a definitive agreement, for the purchase of Preferred Shares in PFM Corporation at a price of
$8.00per share. The termination date of the LOI has since expired but the parties continue to negotiate definitive agreements. If this transaction closes, it is anticipated that the definitive agreements would provide the following proposed terms, among other things, the investor would purchase between
$12,000,000of PFM Corporation Preferred Shares, with such investment to be made in
twoinstallments, with the
secondinstallment to occur within
120days after the initial closing. The Preferred Shares of PFM Corporation to be issued to the investor would be voting securities and, after completion of both closings, depending on the amount of the total investment, the investor could own a majority of PFM Corporation’s issued and outstanding voting securities and Perma-Fix Medical S.A. would own the remaining balance of PFM Corporation’s voting securities. Subject to certain terms and conditions, at each closing, the investor would also receive a warrant to purchase a certain number of shares of PFM Corporation’s common stock. Both warrants would be for a term of
48months and at an exercise price of
oneshare. In addition, at each closing, the Company would receive a
48month warrant, subject to certain terms and conditions, to purchase a certain number of shares of PFM Corporation’s common stock at an exercise price of
$14.00per share. Further, the Company would be repaid
$2,300,000or more of the amounts owed to it by the Medical Segment.
Entire disclosure for the company's acquisition of a controlling interest that does not meet the definition under Accounting Standards Codification 805.
No definition available.